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Abstract
Background: Bowel symptoms are often considered an indication to perform colonoscopy to identify or rule out
colorectal cancer or precancerous polyps. Investigation of bowel symptoms for this purpose is recommended by
numerous clinical guidelines. However, the evidence for this practice is unclear. The objective of this study is to
systematically review the evidence about the association between bowel symptoms and colorectal cancer or
polyps.
Methods: We searched the literature extensively up to December 2008, using MEDLINE and EMBASE and following
references. For inclusion in the review, papers from cross sectional, case control and cohort studies had to provide
a 2×2 table of symptoms by diagnosis (colorectal cancer or polyps) or sufficient data from which that table could
be constructed. The search procedure, quality appraisal, and data extraction was done twice, with disagreements
resolved with another reviewer. Summary ROC analysis was used to assess the diagnostic performance of
symptoms to detect colorectal cancer and polyps.
Results: Colorectal cancer was associated with rectal bleeding (AUC 0.66; LR+ 1.9; LR- 0.7) and weight loss (AUC
0.67, LR+ 2.5, LR- 0.9). Neither of these symptoms was associated with the presence of polyps. There was no
significant association of colorectal cancer or polyps with change in bowel habit, constipation, diarrhoea or
abdominal pain. Neither the clinical setting (primary or specialist care) nor study type was associated with accuracy.
Most studies had methodological flaws. There was no consistency in the way symptoms were elicited or
interpreted in the studies.
Conclusions: Current evidence suggests that the common practice of performing colonoscopies to identify
cancers in people with bowel symptoms is warranted only for rectal bleeding and the general symptom of weight
loss. Bodies preparing guidelines for clinicians and consumers to improve early detection of colorectal cancer need
to take into account the limited value of symptoms.
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Background
Adenocarcinoma of the colon and rectum is the third
most common cancer and the third leading cause of
death in the United Kingdom. In 2004, there were
almost 40,000 new cases diagnosed, and about 16,000
deaths from colorectal cancer [1]. The symptoms with
which colorectal cancer are purported to present most
commonly include alteration in bowel habit, rectal
bleeding, abdominal pain and weight loss [2,3].
Bowel symptoms occur commonly in the community
and are often self limiting. There is little information
available about why or when people seek medical atten-
tion for them [4,5]. Colonoscopies to exclude colorectal
c a n c e ra r ed o n ef r e q u e n t l yf o raw i d er a n g eo fb o w e l
symptoms, a practice suggested by guidelines [6]
although it is unclear which symptoms, if any, improve
the diagnostic yield of cancers or polyps. The costs,
both clinical and financial, of performing colonoscopies
are high. To inform policy, it is therefore important to
assess which symptoms, if any, are associated with can-
cer and precancerous polyps. * Correspondence: b.adelstein@unsw.edu.au
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evidence about the association between bowel symptoms
and colorectal cancer or colorectal polyps.
Methods
Search strategy
We conducted a comprehensive search of the health lit-
erature for all studies evaluating symptoms and colorec-
tal cancer or polyps. The search was undertaken in
December 2008 to identify relevant studies. We
searched MEDLINE (1966-2008) and complete
EMBASE, using a list of symptoms and diagnoses as
MeSH headings; the full search strategy is given in
Additional File 1. The literature selection was based
initially on the paper title, and if thought relevant, fol-
lowed in turn by the abstract or full paper. Foreign lan-
guage papers were translated into English. The literature
search and selection of papers for full review, was car-
ried out independently on two occasions 6 months apart
by one reviewer.
Further, the references included in all selected papers,
as well as review articles, were assessed for possible
inclusion in the systematic review. The citations for
each paper identified for inclusion in the review were
also checked using the cited reference component of the
Web of Science database.
Inclusion criteria
For inclusion in the review, papers had to provide suffi-
cient data about both the symptom and diagnosis (col-
orectal cancer or polyps) and provide a 2×2 table of
symptoms by diagnosis, or the data from which that
table could be constructed. We did not restrict included
papers to certain study types, and we have extensively
explored whether study characteristics had any effect on
the findings. Papers (n = 8) that did not differentiate
between cancers and polyps were excluded. Only full
papers were included: where a relevant conference
abstract was found, the literature was searched for a
more detailed description of the study. If no full paper
was found, the abstract was not included (this occurred
with 1 abstract) [7].
Data extraction and methodological assessment
Extraction of data was performed by one reviewer (BA),
with the complete set of data extracted independently
on two separate occasions 6 months apart. Issues of
uncertainty or discrepancy between the data extraction
sets were referred to a second reviewer (LI); this
occurred in 50% of papers. Agreement was subsequently
obtained at consensus meetings.
For each study, data about methodology, quality and
population characteristics were extracted. Items assessed
included the clinical setting of the study, whether all
participants had at least one symptom or some were
asymptomatic (population type), whether each partici-
pant could have only one or more than one symptom
reported, and study design items (patient recruitment
from general or specialist practice settings, prospective
or retrospective data collection, year of publication, con-
secutive patient recruitment, study type, reference stan-
dard used), and the ease with which data could be
extracted from the paper. We also assessed the preva-
lence of cancer in each paper. The data categories and
the assumptions required to extract the data are shown
in Additional File 2.
One paper described two studies, for which we com-
bined the data [8]. In the same paper, there were ‘don’t
know’ responses that were categorised as “present” for
our analysis. This did not occur in more than 4.4% of
responses.
We used colorectal cancer and polyps only as the two
main outcome measures. Colorectal cancer included
colon and rectal cancer, and included cancers that were
confirmed by histology, as well as cancers listed as such
in the papers but with no criteria given for the diagno-
sis. In general, papers providing information about
polyps did not differentiate between polyps greater or
less than 10 mm, or between different polyp histology;
results are therefore for all polyps.
We have presented results for all symptoms for can-
cer, but for polyps and for comparisons between cancer
and polyps we have included results only for those
symptoms which showed a significant association for
cancer.
Statistical method
The estimated sensitivity and specificity were used to
estimate the diagnostic odds ratio (DOR (=[sensitivity/
(1-sensitivity)]/[(1-specificity)/specificity]) which pro-
vides a single summary measure of test accuracy for
each study. A high DOR indicates high test accuracy; a
test that performs no better than chance in discriminat-
ing between diseased and non-diseased persons has a
DOR of one. Summary ROC (SROC) methods were
used to investigate the accuracy of symptoms for the
diagnosis of colorectal cancer (or polyps); and to investi-
gate whether study methodology, quality and population
characteristics were associated with the diagnostic per-
formance of symptoms. Preliminary exploratory analyses
for each symptom were conducted using the SROC lin-
ear regression method of Moses and Littenberg [9]. The
loge(DOR) was modeled (using unweighted least
squares) as a function of the underlying test positivity
rate (logit (sensitivity) + logit(1-specificity)) which is a
proxy for test threshold. Study and patient characteris-
tics were fitted as covariates. Regression diagnostics
were examined to identify outliers and potentially
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(accuracy) of the SROC curve.
Studies were further analysed using the hierarchical
SROC (HSROC) model of Rutter and Gatsonis [10,11].
This mixed model is more complex, but more rigorous
that the Moses and Littenberg method because it takes
separate account of the uncertainty in the estimates of
sensitivity and specificity within each study, and includes
random study effects for both test accuracy and positiv-
ity criterion (proxy for threshold), thereby taking
account of unexplained heterogeneity between studies.
The model also allows test accuracy to vary with
“threshold” through the inclusion of a scale (shape)
parameter fitted as a fixed effect which provides for
asymmetry in the SROC. Fixed effect covariates were
fitted to assess whether accuracy, positivity criterion or
the shape of the SROC was associated with study or
patient characteristics. Empirical Bayes estimates of
model parameters were obtained using PROC
NLMIXED in SAS [12]. These parameter estimates were
used to obtain summary estimates and 95% confidence
intervals for sensitivity and specificity (summary operat-
ing point), and likelihood ratios. The area under the
SROC curve (AUC) was computed using numerical inte-
gration. Where the summary curve was symmetric, the
DOR is also reported as it is constant across all
thresholds.
Covariates that showed at least very weak association
(p < 0.25) with diagnostic performance in the prelimin-
ary analysis were included in the model to assess
whether test accuracy, the positivity criterion and/or the
shape of the SROC varied with population and study
design characteristics. The chosen level for statistical
significance was 5% (two sided). Where summary ROC
curves being compared had the same shape, the relative
DOR (RDOR) was used as the summary measure of the
relative diagnostic performance, otherwise the AUC was
used. Only results that were robust to the removal of an
influential study are reported.
Comparison of the accuracy of each symptom for the
diagnosis of colorectal cancer versus polyps was
restricted to studies that provided data for both out-
comes. This “paired” analysis, where the diagnosis is
fitted as a covariate in the HSROC model, ensures that
the comparison is not confounded by study or patient
characteristics.
The fitted summary ROC curves derived from the
HSROC model are displayed in ROC space, and are
superimposed on the study specific estimates of sensitiv-
ity and specificity that are denoted by an ellipse. The
horizontal and vertical dimensions of each ellipse are
proportional to the square root of the number of non-
diseased and diseased respectively. A cross is used to
show the summary estimate of sensitivity and specificity.
For the “paired” analyses, the two points for each study
are joined by a line; points are denoted by circles that
do not vary in size for the sake of clarity for these plots.
Ethics approval
As this is a systematic review conducted on previously
published papers and did not use patient level data, no
approval was required.
Results
The literature search yielded 14,121 articles, of which
248 were selected for full review. Three non-English
papers were translated but only one met the inclusion
criteria. We identified 62 eligible papers that provided
relevant information separately for cancers and polyps
[8,13-73]. Studies were published between 1960 and
2008. Quality and study characteristics and descriptors
are shown in Additional File 2.
T h e r ew a saw i d er a n g eo fs y m p t o m si n c l u d e di nt h e
papers, with many papers providing information on sev-
eral symptoms: 26 separate symptoms were included, as
well as 3 combinations of symptoms (for example, bleed-
ing together with change in bowel habit). In addition,
some papers provided information about descriptions of
bleeding. A full list of papers, with all outcomes, and
symptoms is provided in Additional File 3.
The most commonly reported bowel symptoms were
bleeding, change in bowel habit, constipation, diarrhoea
and abdominal pain. Weight loss was the most common
general symptom reported. Overall, only bleeding and
weight loss showed any significant association with can-
cer (Table 1).
Results are presented below for the association
between each symptom and cancer. Where the associa-
tion was significant, results are also presented for the
association between that symptom and polyps.
Rectal Bleeding
Forty papers provided information about the relation-
ship between bleeding (of any type) and colorectal can-
cer
[13-21,23-28,30,32,33,35,37,41,42,45-47,50,51,54-56,60-6-
6,69,72,73], and 23 of these papers [13-17,20,21,23,24,
26,28,30,33,41,42,46,47,54,56,61,63,72,73] also provided
information about the relationship between bleeding
and polyps.
Rectal bleeding was associated with colorectal cancer
(Figure 1). Based on all 40 studies, the AUC was 0.66,
corresponding to a DOR of 2.6 (Table 1). Based on the
summary operating point (shown by a cross on the fig-
ures), bleeding occurred in about half the patients with
cancer (sensitivity 0.46), b u ta l s oo c c u r r e di na b o u ta
quarter of patients without cancer (1-specificity 0.25).
Hence, the likelihood of cancer is approximately doubled
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cancer is present in as many as 5% of people asked about
symptoms, only 9% of those with rectal bleeding will
have cancer. The corresponding likelihood of cancer in
people presenting with no bleeding was LR- = 0.7.
The methodology, quality and population characteris-
tics of the studies also influenced how bleeding was
associated with cancer. The association of bleeding with
colorectal cancer was higher (RDOR 2.2, 95% CI 1.2 -
4.0) when both symptomatic and asymptomatic people
(AUC 0.71), rather than just those with symptoms
(AUC 0.59) were included in the population from which
patients were recruited. The accuracy of bleeding in
diagnosing colorectal cancer was higher when colono-
s c o p y( A U C0 . 6 8 ) ,c o m p a r e dt oa l lo t h e rd i a g n o s t i c
modalities (AUC 0.63), was used as the reference
standard.
Of the 23 “paired” studies that provided information
about bleeding for both cancers and polyps, 18 had a
higher DOR for cancer than for polyps (Figure 2),
resulting in a relative diagnostic odds ratio (RDOR) for
cancer of 1.7 (95% CI 1.5-2.1, p < 0.001). Bleeding gave
an AUC for cancer of 0.63 compared with 0.55 for
polyps. For polyps alone, the DOR was 1.3 (95% CI 1.0-
1.8; p = 0.08).
Table 1 Overview of results: Symptoms association with cancer.
Symptom DOR* (95% CI*) AUC** Sensitivity (95% CI) 1-specificity
(95% CI)
LR+ (95% CI) LR- (95% CI)
Rectal bleeding
# 2.6
(1.9-3.6)
p < 0.001
0.66 0.46
(0.38-0.55)
0.25
(0.19-0.31).
1.9
(1.5-2.3)
0.7
(0.6-0.8)
Blood mixed with stool: 3.1
(2.0-4.8)
p < 0.001
0.68 0.49
(0.30-0.69)
0.24
(0.13-0.40)
2.1
(1.5-2.8)
0.7
(0.5-0.9)
Blood: dark red 3.9
(1.7 - 9.2)
P = 0.004
0.71 0.29
(0.09-0.65)
0.10
(0.03-0.28)
3.1
(1.6-6.0)
0.8
(0.6-1.1)
Change in bowel habit 1.5
(0.8-2.8)
p = 0.16
0.57 0.32
(0.21-0.46)
0.24
(0.15-0.35)
1.4
(0.9-2.1)
0.9
(0.7-1.1)
Constipation 1.1
(0.8-1.5)
p = 0.48
0.52 0.12
(0.08-0.18)
0.11
(0.07-0.16).
1.1
(0.8-1.5)
1.0
(1.0-1.0)
Diarrhoea 0.9
(0.4-1.7)
p = 0.65
0.47 0.15
(0.07-0.28)
0.17
(0.09-0.29)
0.9
(0.5-1.6)
1.0
(0.9-1.1)
Abdominal pain 0.7
(0.5-1.1)
p = 0.12
0.45 0.19
(0.13-0.28)
0.24
(0.17-0.33).
0.8
(0.6-1.1)
1.1
(1.0-1.2)
Weight loss 2.9
(1.6-5.0)
p = 0.001
0.67 0.20
(0.12-0.31)
0.08
(0.05-0.13).
2.5
(1.5-4.0)
0.9
(0.8-1.0)
*DOR = diagnostic odds ratio. No association between symptom and cancer if DOR = 1
**AUC = area under the Receiver operating characteristic curve. No association between symptom and cancer if AUC = 0.5
# Bleeding of any type
Note: Results for bleeding types for which there 3 or more papers or for which the DOR was > 1 are shown. Results for other bleeding types are shown in
Additional File 4.
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Figure 1 Bleeding: SROC for cancer. SROC = Summary ROC crc =
colorectal cancer. The horizontal and vertical dimensions of the
each ellipse are proportional to the square root of the number of
non-diseased and diseased respectively. + shows the expected
sensitivity and 1-specificity for the curve. The diagonal line joining
(0,0) and (1,1) represents an ROC of no diagnostic value.
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Few papers provided information about bleeding type
(details provided in Additional File 4) [8,19,31,34,41,
48,49,59,62]. Of these, only bleeding mixed with stool
and dark red blood had DORs consistently above 1. For
bleeding mixed with stool the summary DOR was 3.1
(95% CI 2.0 - 4.8, p < 0.001), and the AUC 0.68. For
dark red blood, the DOR was 3.9 (95% CI 1.7 - 9.2, p <
0.01), and the AUC was 0.71. No DOR and AUC was
estimated for bright red bleeding, because this was
reported in only 3 papers, for which the odds ratios
were 0.9, 1.1 and 1.1 (Additional File 4).
Weight loss
Eighteen papers provided information about the rela-
tionship between weight loss and colorectal cancer
[8,18,19,22,25,26,32,34,35,37,47-49,55,59,61-63], and six
of these papers [26,47-49,61,63] also provided informa-
tion about the relationship between weight loss and
polyps.
Weight loss was associated with colorectal cancer,
with an AUC of 0.67, corresponding to a DOR of 2.9
(Table 1 Figure 3). Weight loss occurred in 20% of the
patients with cancer (sensitivity 0.20), and occurred in
less than 10% without cancer (1-specificity 0.08). Hence,
the likelihood of cancer was more than doubled in peo-
ple presenting with weight loss (LR+ = 2.49). The corre-
sponding likelihood of cancer in people presenting with
no weight loss was LR- = 0.9.
Of the 6 “paired” studies that provided information
about weight loss for both cancers and polyps, 5 had a
higher DOR for cancer than for polyps (Figure 4),
resulting in a RDOR of 5.2 (95% CI 2.8 - 9.6, p < 0.001).
Weight loss showed better discrimination for cancer
(AUC 0.70) than for polyps (AUC 0.44). Weight loss did
not have a significant association with polyps (DOR 0.7,
95% CI 0.3 - 1.5, p = 0.22).
Change in bowel habit, constipation, diarrhoea and
abdominal pain were not associated with colorectal can-
cer (Table 1 Figure 5, Figure 6, Figure 7, Figure 8).
Discussion
Principal findings
The symptoms usually considered important for color-
ectal cancer diagnosis are rectal bleeding, change in
bowel habit, abdominal pain, weight loss, diarrhoea
and constipation. Of these, in our systematic review,
only weight loss and rectal bleeding were associated
with colorectal cancer, albeit with low DORs and
AUCs. There was evidence that the other symptoms
were not associated with colorectal cancer. Accuracy
did not vary by primary care or specialist setting, or
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Figure 2 Bleeding: cancer and polyp comparison.c r c=
colorectal cancer. The horizontal and vertical dimensions of the
each ellipse are proportional to the square root of the number of
non-diseased and diseased respectively. + shows the expected
sensitivity and 1-specificity for the curve. The paired points (one
black and one open joined by a dotted line) represent a within
study comparison. The diagonal line joining (0,0) and (1,1)
represents an ROC of no diagnostic value.
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Figure 3 Weight loss: SROC for cancer.S R O C=S u m m a r yR O C .
crc = colorectal cancer. The horizontal and vertical dimensions of
the each ellipse are proportional to the square root of the number
of non-diseased and diseased respectively. + shows the expected
sensitivity and 1-specificity for the curve. The diagonal line joining
(0,0) and (1,1) represents an ROC of no diagnostic value.
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Figure 4 Weight loss: cancer and polyp comparison.c r c=
colorectal cancer. The horizontal and vertical dimensions of the
each ellipse are proportional to the square root of the number of
non-diseased and diseased respectively. + shows the expected
sensitivity and 1-specificity for the curve. The paired points (one
black and one open joined by a dotted line) represent a within
study comparison. The diagonal line joining (0,0) and (1,1)
represents an ROC of no diagnostic value.
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Figure 5 Change in bowel habit: SROC for cancer.S R O C=
Summary ROC. crc = colorectal cancer. The horizontal and vertical
dimensions of the each ellipse are proportional to the square root
of the number of non-diseased and diseased respectively. + shows
the expected sensitivity and 1-specificity for the curve. The diagonal
line joining (0,0) and (1,1) represents an ROC of no diagnostic value.
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Figure 6 Constipation: SROC for cancer. SROC = Summary ROC.
crc = colorectal cancer. The horizontal and vertical dimensions of
the each ellipse are proportional to the square root of the number
of non-diseased and diseased respectively. + shows the expected
sensitivity and 1-specificity for the curve. The diagonal line joining
(0,0) and (1,1) represents an ROC of no diagnostic value.
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Figure 7 Diarrhoea: SROC for cancer. SROC = Summary ROC. crc
= colorectal cancer. The horizontal and vertical dimensions of the
each ellipse are proportional to the square root of the number of
non-diseased and diseased respectively. + shows the expected
sensitivity and 1-specificity for the curve. The diagonal line joining
(0,0) and (1,1) represents an ROC of no diagnostic value.
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able across settings.
The lack of clinical usefulness of symptoms is also
confirmed by the positive likelihood ratio of the symp-
toms. To provide strong evidence for ruling in disease, a
positive likelihood ratio should be greater than 10 [74].
Faecal occult blood tests have been shown to have posi-
tive likelihood ratios of up to 47.39 [75]. Weight loss
was the symptom with the highest positive likelihood
ratio: 2.5. This means that a person with weight loss has
less than a 3-fold increase in colorectal cancer risk.
However, weight loss is gener a l l yan o n - s p e c i f i cs y m p -
t o m ,a n di nm o s to ft h es t u d i e si n c l u d e di nt h i sm e t a -
analysis was analysed in a population already selected
for being of sufficiently high risk of colorectal cancer to
warrant investigation for colorectal cancer. Apart from
weight loss and rectal bleeding, the positive likelihood
ratio of other symptoms was around one. Our review
also suggests that, even when symptoms are associated
with cancer, they are not associated with polyps.
Previous systematic reviews of symptoms also found
that clinical features have limited predictive value in
identifying patients with cancer [76,77], although a sys-
tematic review of rectal bleeding in combination with
other symptoms showed that this had modest diagnostic
value [78]. Another review, assessing only those symp-
toms with a predictive value of > 5%, has also identified
that some symptoms may be of some value [79]. Our
review is based on a larger number of studies, evaluated
both cancer and polyps, applied a more rigorous metho-
dology, using hierarchical summary ROC method that
takes into account unexplained heterogeneity between
studies, and included assessment of whether study
design or population characteristics affected the results.
Quality of studies
Our review showed that most studies had methodologi-
cal flaws. For example, the reference standard differed
between studies and fewer than half the papers used
colonoscopy to identify cancer and polyps. We have
shown that the studies that used colonoscopy showed a
somewhat stronger association between rectal bleeding
and cancer (AUC 0.68) than when other methods were
used to determine the presence of cancer (AUC 0.63).
This is presumably because the association is underesti-
mated when using a poorer reference standard [80].
However, most other measures of study quality were
not shown to affect the results. Nevertheless, the quality
of studies and their reporting should be improved. For
example, we found that in over half the papers there
were data discrepancies or miscalculations within the
papers. While most of these were minor, 10% required
some assumptions to extract the data. Adherence to
quality criteria such as the STARD checklist and flow
diagram would ensure that the quality of reporting [81].
Symptom presentation, and their predictive value, may
be affected by the patient’s age. However, the papers
analysed did not present symptom and outcome infor-
mation in sufficient detail to explore this relationship.
There was also no consistency between studies in the
way in which symptoms were elicited or interpreted.
Indeed very few studies provided information about how
symptoms were elicited and did not characterise them:
for example while some studies defined rectal bleeding
as the first episode of bleeding or gave a time limit dur-
ing which the bleeding occurred, the majority of studies
provided no definition at all. Similarly, few studies gave
definitions for constipation or diarrhoea or differentiated
this from change in bowel habit. Also, there is potential
for recall bias, with few studies providing information
about when the symptoms were elicited in relation to
when the diagnosis was made. In some studies symp-
toms were obtained from medical records, in other stu-
dies they were recorded during a consultation. In other
studies a specific questionnaire was used, sometimes
administered as part of the medical consultation and in
others administered either by a researcher specifically
for the study, or completed by the patients themselves.
To do better studies in the future, a standardised repea-
table method of eliciting symptoms is needed and is
now available [82]. In practice symptoms are seldom
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Figure 8 Abdominal pain: SROC for cancer.S R O C=S u m m a r y
ROC. crc = colorectal cancer. The horizontal and vertical dimensions
of the each ellipse are proportional to the square root of the
number of non-diseased and diseased respectively. + shows the
expected sensitivity and 1-specificity for the curve. The diagonal line
joining (0,0) and (1,1) represents an ROC of no diagnostic value.
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as well as with other patient characteristics. Where this
has been done, it has been found that some additional
symptoms may improve diagnostic value [78]. However,
few studies have presented such information, and there
is a need for a well conducted primary study to evaluate
this.
Conclusions
Our systematic review has shown that, on current evi-
dence, only rectal bleeding and the general symptom of
weight loss are associated with colorectal cancer, and
may be helpful in selecting patients for further investiga-
tion with colonoscopy. Until such time as better studies
are done, it seems wise to channel resources for cancer
detection towards population based screening pro-
grammes using FOBT rather than relying on identifying
all cancers and precancerous polyps through investigat-
ing people with symptoms.
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